NephJC is a nephrology journal club that uses Twitter to discuss the research, guidelines, and editorials that drive nephrology.
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
Upcoming Twitter chats:
All scheduled chats are tentative. We may change the schedule depending on the whims of the NephJC work group.
May 14, 15 NephJC: Does Rate of Correction of HypERnatremia matter?
May 21 #AskASN: KidneyX
May 28, 29 NephJC: A new risk score for IgA Nephropathy
June #AskASN Kidney Health Initiative with new co-chair Dr. Ray Harris
June 11, 12 NephJC: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial (SONAR)
June 25, 26 NephJC: Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial
July NephJC Summer Book Club with Doctor (Object Lessons) by Andrew Bomback
July #AskASN Fellow Talk
August #AskASN: Why you must go to Kidney Week
September #AskASN: Renal Educator’s Community
Recent discussions
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
Please use our visual abstracts, blogs and podcasts. Please be considerate and credit the creators as well.
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
The NephJC Twitter Journal Club Primer
The NephJC work group has produced a primer to document some of our thoughts on the practices on running a Twitter Journal Club. We think it is quite good. Take a look.
In the last year, NephJC has injected some statistical muscle into its editorial team (thank you Perry Wilson and Laurie Tomlinson). Then Manasi Bapat volunteered to create some cogent explainers for the various techniques that are routinely described in the methods section most of us skip over as we rush to the results. Here are the recent posts...
NephTrials: where NephJC joins forces with ISN ACT and ISN Academy, to bring the social media expertise from the NephJC community and the methods expertise from ISN-ACT.
In this edition of #Nephstats, we look at Number Needed to Treat (NNT), a controversial topic creates ripples and roars on social media amongst stat savvy physicians, epidemiologists and biostatisticians. This seems like such a simple and easy number to make sense of a trial’s importance - what could be controversial or wrong about it?
How do you understand the inverted world of non-inferiority? Manasi Bapat breaks it down for us here
She’s back: A stats explainer of statistical modelling, goodness of fit and the Bayes information criterion from Manasi Bapat.
When a study is negative the work is not done. Time to separate a negative trial from an underpowered one. Learn how to think about this with Manasi Bapat.
Multiple testing and the Bonferroni - NSMC intern and NephJC stats explainer Manasi Bapat breaks it down for you in this post.
Manasi deconstructs pragmatic trials for us. How are they different compared to efficacy & explanatory trials?
Manasi Bapat takes you behind the scenes to explain the need for doing sensitivity analyses
We begin a series of occasional commentary on the methods underlying the research being discussed. This edition: the 2 x 2 factorial designs.
Please use our visual abstracts, blogs and podcasts. Please be considerate and credit the creators as well.
We have a patient perspective on the new IgA Guidelines and what it means to live with IgA in these times.
Steve Quinlan is a patient who did PD for a year. He looked at the 2020 ISPD guidelines of adequacy and he has thoughts…
A patient voice from the mother of an individual with IgA Nephropathy who went on to found the IgA Nephropathy Foundation
Kevin Fowler gives his take on what it means to be a kidney transplant recipient living with skin cancer - and what he envisions as research needs in this area.
A patient perspective on ADPKD - and how the new research holds meaning for someone living with ADPKD.
Getting ‘THE CALL’ for a deceased donor organ transplant….and coming to know it is from a high risk or increased risk donor. From someone who was has died of a drug overdose. What does it mean for a patient on dialysis eager to stop dialysis - but worried about receiving a gift that lasts? Susan Kjos explores the dilemma
Please use our visual abstracts, blogs and podcasts. Please be considerate and credit the creators as well.
An interview about our experiment with conference coverage of simultaneously published studies
Please use our visual abstracts, blogs and podcasts. Please be considerate and credit the creators as well.
An interview about our experiment with conference coverage of simultaneously published studies
On Sunday morning during the NephJC Editorial Internship graduation, the Winners of the 2026 NephJC Kidneys were revealed
The NephJC Book Club
is an annual tradition. Every summer we blog our way through a book of medical interest and have a Twitter-based book club discussion.
2019 Andrew Bomback’s Doctor (Object Lessons)
2018 Siddhartha Mukherjee's Laws of Medicine, Field Notes from an Uncertain Science
2017 Vanessa Grubb's, Hundreds of Interlaced Fingers.
2016 Eric Topol's, The Patient Will See You Now
2015 Atul Gawande's, Being Mortal
The winners of the third annual NephJC Kidneys
Thanks for voting. On Oct 26th at the #KidneyWk Beach Party we announced the winners in all 5 categories.
Rookie of the Year: Mohamed Elrggal
Most Engaged Scientist: Marvin Gonzalez
Study of the Year: A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops
Most Valuable Player: Maryam Khosravi
Nathan Hellman Social Media Project of the Year: The GlomCon Interactive Fellows’ Curriculum
See some great pictures from the event here.